Conference Material
|
Video
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
Solomos A
Share
Share
Similar Content
Slide Presentation
|
Slide Presentation
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
2023 June 07 • MSF Scientific Day International 2023
Abstract
|
Abstract
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
2023 June 07 • MSF Scientific Day International 2023
Loading...
Countries
Ethiopia
Kenya
Uganda
Sudan
Subject Area
neglected tropical diseases
kala azar
Languages
English
DOI
10.57740/a51f-3605
Published Date
07 Jun 2023
Conference
MSF Scientific Day International 2023
Linked Content
Conference Material
|
Slide Presentation
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
2023 June 07 • MSF Scientific Day International 2023
Conference Material
|
Abstract
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
2023 June 07 • MSF Scientific Day International 2023
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial | Conference Material / Video | MSF Science Portal
